Background {#Sec1}
==========

Urinary tract infections (UTIs) are common infectious diseases in both hospital- acquired UTI (HAUTI) and community-acquired UTI (CA-UTI) \[[@CR1], [@CR2]\]. UTI can be diagnosed by at least one of the following clinical symptoms or signs; temperature ≥ 38 °C, suprapubic pain, costovertebral angle pain, urinary urgency, dysuria or frequency. A quantitative urine culture with bacterial counts ≥10^5^ colony forming units per mL (CFU/mL) is essential for the diagnosis of UTI \[[@CR3]\]. UTIs may be caused by gram-negative, gram-positive bacteria or by fungi. *E. coli* is the most common cause followed by *Klebsiella* and other *Enterobacteriaceae* in both CA-UTI \[[@CR4]\] and hospital- acquired UTI (HAUTI) \[[@CR5]\]. Fluoroquinolones (FQs) have been considered a highly effective treatment of UTIs. However, the development of resistance to these agents especially by gram-negative microorganisms complicates the treatment of infections caused by these organisms \[[@CR6]\]. FQs resistance is mainly caused by spontaneous mutations in the quinolone resistance determining regions (QRDR) of *gyr* A and *par* C genes, either *gyr* A or *par* C, or both genes \[[@CR7]\]. However, in the past few decades, plasmid-mediated quinolone resistance (PMQR) has been increasingly reported in *Enterobacteriaceae* species all over the world \[[@CR8]\]. The co-existence of mutations in QRDR and PMQR genes carriage can occur together in *Enterobacteriaceae* species. Moreover, the presence of PMQR determinants may promote QRDR mutations increasing the FQs resistance rates \[[@CR9]\]. Some studies in Egypt have previously investigated the FQs resistance \[[@CR10], [@CR11]\], but the study of contribution of various mechanisms of resistance in different *Enterobacteriaceae* species in immunocompetent patients was not addressed. Accordingly, the aim of the current study was to investigate antimicrobial resistance of different *Enterobacteriaceae* species isolated from CA-UTI and HAUTI against FQs and correlate its levels with the existing genetic mechanisms of quinolones (Qs) resistance.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This is a cross-sectional study was conducted in Minia university hospitals, Egypt, from July 2016 to March 2017. A total of 705 patients with suggested UTI (presented with one or more of UTI symptoms;(Fever ≥38 °C, dysuria, increased frequency and suprapubic pain) were included in the study. Urine samples with positive pyuria and urine cultures with a colony count for a single bacterial species ≥10^5^ CFU/mL were only included. The study populations were adults (\> 18 years). About 32.2% of participants were males and 67.8% were females. The study included 418 outpatients (attended at outpatient's clinics seeking the treatment) and 286 inpatients (developed their clinical symptoms after 48 h of admission). This study was carried out according to the principles of the declaration of Helsinki. The study was approved by the Medical Ethics Committee of Minia university Hospital, Egypt. As the study used anonymous clinical data, the patients were not required to give informed consent for the study (code: 45 A at 2/5/2016).

Bacterial strains {#Sec4}
-----------------

Urine specimens were collected from symptomatic patients in sterile screw capped containers that were transported within 2 h of collection to bacteriology laboratory in an ice box and processed at once. Well-mixed uncentrifuged urine specimens were streaked by semi-quantitative streaking method onto UTI chrome agar (CHROMagar™ Orientation, paris, France) and by calibrated loop technique on MacConkey and blood agars \[[@CR12]\]. After overnight incubation at 37 °C, isolated uropathogens were further identified according to their phenotypic criteria based on gram staining, cultural characters and biochemical testing including indole, urease, citrate and sugar fermentation tests \[[@CR12]\]. Confirmed *Enterobacterecieae* strains were kept in trypticase soy broth with sterilized 15% glycerol at − 20 °C. A total of 440 non-repetitive *Enterobacterecieae* isolates were recovered from urine samples.

Antimicrobial susceptibility testing {#Sec5}
------------------------------------

According to CLSI guidelines \[[@CR13]\], disk diffusion method was used to determine antimicrobial susceptibility of the *Enterobacteriaceae* isolates to different antibiotics; amoxicillin/clavulanic acid (AMC) 30 μg, ceftriaxone (CRO) 30 μg, ceftazidime (CAZ) 30 μg, imipenem (IPM) 10 μg, amikacin (AK) 30 μg, sulphamethoxazole/ trimethoprim (SXT) 25 μg, and nitrofurantoin (F) 300 μg. Also 4 different antibiotics discs for quinolone (Q) and fluoroquinolones (FQs) resistance were used; nalidixic acid (NA) 30 μg, ciprofloxacin (CIP) 5 μg, norfloxacin (NOR) 10 μg and ofloxacin (OFX) 5 μg (Thermo Scientific™ Oxoid, UK). Minimum inhibitory concentration (MIC) of ciprofloxacin (CIP) was determined by two methods; MIC strips (E test) which graded from 0.002 to 32 μg/mL and agar dilution method. MIC strips (E test) (Liofilchem s.r.l, Italy) were placed on surfaces of inoculated Mueller-Hinton agar plates as explained previously \[[@CR12]\]. MIC determination by agar dilution method was performed according to CLSI guidelines (CLSI, 2015 and CLSI\*, 2015), where ten concentrations (4--2048 μg/mL) of CIP were prepared (each in a single agar plate) \[[@CR14], [@CR15]\]. The results of disk diffusion assay as well as MIC were interpreted according to CLSI guidelines \[[@CR13]\].

DNA extraction and PCR amplification {#Sec6}
------------------------------------

DNA was extracted using GeneJET genomic DNA purification kit (Thermosceintific, USA) according to the manufacturer's instructions. PMQR genes; *qnrA, qnrB* and *qnrS* were tested by a multiplex PCR reaction using specific primers (Table [1](#Tab1){ref-type="table"}). PCR was performed in a 25 μL reaction mixture containing 5 μL of purified DNA (approximately 500 ng/휇L), 12.5 μL of Platinum® multiplex PCR master Mix (Applied Biosystems™, USA), 0.8 휇L (8 pmol) of each primer and 2.7 μL of nuclease free water. Single PCR reactions were used for amplification of each of PMQR genes (*qnrC* and *qepA)* and QRDRs of *gyrA* and *parC* genes using specific primers (Table [1](#Tab1){ref-type="table"}). Each single PCR reaction was performed in a 25 μL reaction mixture containing 300 ng/휇L of DNA, 12.5 μL of AmpliTaq Gold® 360 master mix (Applied Biosystems™, USA), 1 μL (10 pmol) of each primer and 7.5 μL of nuclease free water. The primers sequences, annealing temperature, and size of amplified fragments for the studied genes are shown in Table [1](#Tab1){ref-type="table"} \[[@CR16]--[@CR20]\]. PCR products were resolved on 1% agarose gel with ethidium bromide dye and the gel was visualized under a UV transilluminator (Biometra Goettingen, Germany). Table 1PCR primers used in the current studyPrimer namePrimer sequence (5^/^ to 3^/^)PCR product size (bp)Annealing TemperatureRef*qnrA* m-FAGAGGATTTCTCACGCCAGG58054 °C\[[@CR16]\]*qnrA* m-RTGCCAGGCACAGATCTTGAC*qnrB* m-FGGMATHGAAATTCGCCACTG26454 °C\[[@CR16]\]*qnrB* m-RTTTGCYGYYCGCCAGTCGAA*qnrS* m-FGCAAGTTCATTGAACAGGGT42854 °C\[[@CR16]\]*qnrS* m-RTCTAAACCGTCGAGTTCGGCG*qnrC*-FGGGTTGTACATTTATTGAATC44750 °C\[[@CR17]\]*qnrC*-RTCCACTTTACGAGGTTCT*qepA*-GFACATCTACGGCTTCTTCGTCG50255 °C\[[@CR18]\]*qepA*-GRAACTGCTTGAGCCCGTAGATC*parC-*FATG TAC GTG ATC ATG GAC CG30055 °C\[[@CR19]\]*parC*-RATT CGG TGT AAC GCA TCG CC*gyrA*-FAAA TCT GCC CGT GTC GTT GGT34355 °C\[[@CR20]\]*gyrA*-RGCC ATA CCT ACG GCG ATA CC

Sequencing of PCR products {#Sec7}
--------------------------

Sequencing was carried out using an automated DNA sequencer and data collection software from Applied Biosystems, USA. Translated nucleotide sequences of QRDR in *gyrA* and *parC* genes were compared with corresponding reference protein sequences using BLAST software of NCBI; National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/blast>). *GyrA* accession number used for *E. coli* was WP_074153749.1, for *Klebsiella* spp. was WP_075874334.1 and for *Citrobacter* spp. was WP_044266198.1. Accession number for *parC* was AML00471.1.

Statistical analysis {#Sec8}
--------------------

Statistical analysis of demographic, clinical and laboratory data of study subjects was performed using SPSS for windows version 19.0 (IBM, USA).

Results {#Sec9}
=======

Prevalence of *Enterobacteriaceae* strains among UTIs {#Sec10}
-----------------------------------------------------

Four hundred and forty isolates belonging to *Enterobacteriaceae* family were recovered from UTI patients with a percentage of (440/705, 62.4%). Two hundred and nine (209/286, 73.1%) were from inpatients and (231/418, 55.1%) were from outpatients. *E. coli* was the most frequent pathogen (281/440 (63.9%), followed by *Klebsiella pneumoniae* (*K. pneumoniae)* (81/440, 18.4%), *Citrobacter* spp. (47/440, 10.7%), *Proteus* spp. (20/440, 4.5%) and lastly *Enterobacter* spp. (11/440, 2.5%), (Table [2](#Tab2){ref-type="table"}). Table 2prevalence of different species of *Enterobacteriaceae* isolated from UTIsOrganismFrequency*P* valueTotalOutpatientsInpatientsN%N%N%*E.coli*28163.9%14763.6%13464.1%0.0001*K. pneumoniae*8118.4%4017.3%4119.6%*Citrobacter* spp.4710.7%177.4%3014.4%*Enterobacter* spp.112.5%93.9%21.0%*Proteus* spp.204.5%187.8%21.0%Total440100%231100%209100%*UTIs* Urinary tract infections

Antimicrobial susceptibility profiles of *Enterobacteriaceae* isolates {#Sec11}
----------------------------------------------------------------------

Of 440 *Enterobactericeae* clinical isolates tested for antimicrobial susceptibility, the highest rates of resistance were observed against SXT (253/440, 57.5%), CRO (217/440, 49.3%) and AMC (159/440, 36.1%). while the highest susceptibility rate was found to IMP (440/440, 100%). Percentages of resistant isolates to tested antimicrobial agents are summarized in Table [3](#Tab3){ref-type="table"}. Table 3Patterns of antimicrobial resistance of *Enterobacteriaceae* species isolated from UTIsAntibioticAMCCTZCROIMPAKSXTNACIPNOROFXForganismN%N%N%N%N%N%N%N%N%N%N%*E.coli*9935.29734.515956.60.06322.418264.8104375419.25419.25419.26924.6*K. pneumoniae*1721.01316.01619.80.0911.12935.81113.6911.1911.1911.11214.8*Citrobacter* spp*.*3166.02042.63063.80.01021.32246.81736.21715.61715.61715.61940.4*Enterobacter* spp*.*19.119.119.10.019.1218.219.100000000.0*Proteus* spp.1155.01155.01155.00.015.01890.01050109.2109.2109.21050Total15936.114232.321749.30.08419.125357.514332.59020.59020.59020.511025*AMC* Amoxicillin Clavulanic acid, *CTZ* Ceftazidime, *CRO* Ceftriaxone, *IMP* Imipenem, *AK* Amikacin, *SXT* Sulphamethoxazole-Trimethoprim, *NA* Nalidixic acid, *CIP* Ciprofloxacin, *NOR* Norfloxacin, *OFX* Ofloxacin, *F* Nitrofurantoin

Quinolone (Q) and fluoroquinolones (FQs) susceptibility {#Sec12}
-------------------------------------------------------

A total of (143/440, 32.5%) *Enterobacteriaceae* isolates were resistant to one or more of the tested (Q and FQs). Out of them (90/440, 20.5%) were resistant to FQs. These isolates could be categorized into three phenotypes; high resistance phenotype which included 67 isolates that were highly resistant to all tested Q and FQs with MIC of CIP \> 32 μg/mL, intermediate resistance phenotype which included 23 isolates with intermediate resistance to all tested Q and FQ with MIC of CIP =1--2 μg/mL. FQs susceptible phenotype which included 53 isolates that were resistant to NA only (Q) and susceptible to all tested FQs with MIC of CIP ≤ 1 μg/mL.

Prevalence of PMQRs {#Sec13}
-------------------

Of the 143 Q resistant isolates, 90 isolates (62.9%) harbored at least one PMQR gene (54 *E. coli*, 17 *Citrobacter*, 9 *K. pneumoniae* and 10 *Proteus).* The most frequent PMQR gene was *qnrB*, which was detected in (90/143, 62.9%) of Q and FQs resistant isolates and in (90/90, 100%) of FQs resistant isolates. Q*nrS* gene was detected in (67/143, 46.9%) of Q and FQs resistant isolates and in (67/90, 74.4%) of FQs resistant isolates (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Neither *qnrA* nor *qnrC* were detected in the studied isolates. *qepA* gene was detected in (9/143, 6.3%) of Q and FQs resistant isolates and in (9/90, 10%) of FQs resistant isolates. (Additional file [2](#MOESM2){ref-type="media"}: Figure S2) (Table [4](#Tab4){ref-type="table"}). Table 4distribution of PMQR and QRDRs among different FQs resistance phenotypes of *Enterobacteriaceae* isolated from UTIsSpeciesPhenotypeResistant to QuinolonesPMQR genesMIC of CIP (μg/mL)NumbergyrA alterationsParC alterations*E.coli*FQ SusceptibleNA onlyNo genes detected0.531Ser83LeuNo mutation0.2519Ile155PheSer80IleIntermediate resistanceNA, CIP, NOR, OFX*qnrB*1.57His80MetGly81AlaSer83LeuMet118TrpArg119Val213Ser83LeuNo mutationHigh resistanceNA, CIP, NOR, OFX*qnrB, qnrS*12828Ser83TyrLys154ArgSer171AlaIle174ThrAla175ValSer80IleHigh resistanceNA, CIP, NOR, OFX*qnrB, qnrS, qepA*128, 256, 5126Asp87AsnSer80Ile*K. pneumoniae*FQ SusceptibleNA onlyNo genes detected0.52Lys154ArgAla171SerNo mutationIntermediate resistanceNA, CIP, NOR, OFX*qnrB*22No mutationSer80IleHigh resistanceNA, CIP, NOR, OFX*qnrB, qnrS*1283Ser83TyrSer80IleMet118Ile5124Ser83TyrAla175ArgVal176LeuSer80IleMet118Ile*Citrobacter* spp.Intermediate resistanceNA, CIP, NOR, OFX*qnrB*1.51NDNDHigh resistanceNA, CIP, NOR, OFX*qnrB, qnrS*25615Ser83IleLys154ArgSer171AlaSer80IleHigh resistanceNA, CIP, NOR, OFX*qnrB, qnrS, qepA*5121*Enterobacter* spp.FQ susceptibleNA onlyNo genes detected0.1251NDND*Proteus* spp.High resistanceNA, CIP, NOR, OFX*qnrB, qnrS*125--5128NDNDHigh resistanceNA, CIP, NOR, OFX*qnrB, qnrS, qepA*2NDND*PMQR* Plasmid-mediated quinolone resistance, *QRDR* Quinolone resistance determining regions, *CIP* Ciprofloxacin, *ND* Not determined

QRDR mutations in *gyrA* and *parC* genes {#Sec14}
-----------------------------------------

Q and FQs resistant isolates were studied by PCR and subsequent sequencing of QRDR of their *gyrA* and *parC* genes. Mutation at codon 83 of *gyrA* was detected in (102/143, 71.3%) of Q resistant isolates; 51 of them belong to high resistance phenotype, 20 in intermediate phenotype and 31 belong to the FQs susceptible phenotype (resistant to NA only) (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Mutation at codon 87 (Asp87Asn) of *gyrA* was detected in high resistance phenotype only (6 isolates) (Fig. [3](#Fig3){ref-type="fig"}). Three types of amino acid changes resulted from mutation at codon 83 of *gyrA* protein; change from serine to leucine in *E. coli*, from serine to tyrosine which was detected in *E. coli* and *Klebsiella* and from serine to isoleucine in *Citrobacter* strains. Mutation at position 80 of *parC* gene was detected in (78/143, 54.5%) of isolates (Fig. [4](#Fig4){ref-type="fig"}); 57 of them belong to high resistance phenotype, 2 isolates (intermediate resistance) and 19 isolates (FQs susceptible phenotype). Isolates' identification, phenotypes, PMQR genes distribution and detected mutations are summarized in (Table [4](#Tab4){ref-type="table"}). Fig. 1Alteration in *gyr A* (codon 83). Nucleotide sequence of a *gyrA* region of the *E. coli* FQs-susceptible, WP_074153749.1 DNA gyrase subunit A (*E. coli*). Alteration in (codon 83) Fig. 2Alteration in *gyr A* (codon 83, 154, 171). Nucleotide sequence of a *gyrA* region of the *Citrobacter* spp. high resistance isolates, WP_044266198.1 DNA gyrase subunit A (*Citrobacter)*. Alteration in (codon 83, 154, 171) Fig. 3Alteration in *gyr A* (codon 87). Nucleotide sequence of a *gyrA* region of the *E. coli* high resistance isolates, WP_074153749.1 DNA gyrase subunit A (*E. coli*) Alteration in (codon 87) Fig. 4Alteration in *par C* (codon 83). Nucleotide sequence of a *parC* region of the *E. coli* high resistance isolates, Reference Sequence Strain. AML00471.1 DNA topoisomerase IV. Alteration in (codon 80)

Correlation between phenotyping and genotyping of resistant isolates {#Sec15}
--------------------------------------------------------------------

All isolates with high resistance phenotype (67) harbor *QnrB* and q*nrS* genes. Q*epA* gene was detected in only 9 isolates with high resistance phenotype. Isolates with intermediate resistance phenotype (23) carry *qnrB* gene only. None of PMQR genes was found in isolates with FQs susceptible isolates (resistant to NA only). Detection of PMQR genes (*qnrB* and *qnrS*) was strongly correlated with FQs resistance levels in resistant isolates with a correlation coefficient equal to 0.8 (r = 0.8) and 0.9 (r = 0.8) respectively which was highly significant (*p* value; 0.0001) for both genes as well as *qepA* gene with a correlation coefficient equal to 0.25 (r = 0.25) which was considered fair but significant (*p* value; 0.006). Detection of specific mutations in *gyrA* and *parC* genes was not correlated with susceptibility pattern to tested Q and FQs as these mutations were found in all phenotypes (Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec16}
==========

UTIs are common bacterial infections in hospital settings and community \[[@CR21]\]. In the current study, 440 *Enterobacteriaceae* isolates were isolated from UTIs with a percentage of (440/705, 62.4%). The isolation rates from inpatients and outpatients were (73.1%) and (55.1%) respectively. A higher frequency of isolation (86%) was recorded previously in Asia-Pacific region \[[@CR22]\]. The frequency of isolation from outpatients agrees with a previous report in Ethiopia (57.75%) \[[@CR23]\], and disagrees with another report in Korea (89%) \[[@CR4]\]. *E. coli* was the most frequent followed by *K. pneumoniae*, *Citrobacter* spp.*, Proteus* spp. and lastly *Enterobacter* spp. These findings agree with several previous studies \[[@CR24], [@CR25]\]. In spite of similarity with these reports, *Citrobacter* spp*.* isolation rate in the current study remains the highest. The highest antimicrobial resistance rates were recorded in the present study against SXT with a percentage of (57.5%) followed by CRO (49.3%), however, none of the isolates were resistant to imipenem. These findings agree with several previous studies \[[@CR4], [@CR5]\]. High resistance to CRO may be caused by extensive use in the locality. NA has been used for treatment of UTIs for more than five decades \[[@CR26]\] so the resistance to NA is expected to be higher than to FQs. In the current study, NA has a resistance rate of (143/440, 32.5%), however higher rates were reported previously in several studies \[[@CR23], [@CR25], [@CR27]\]. The fact that NA is not an empiric treatment of UTI in Egypt may be the cause of this difference. FQs have an overall resistance rate of (90/440, 20.5%). Near results were reported in Korea (24.8%) \[[@CR4]\], while a higher resistance rate (54.9%) was recorded in Asian countries \[[@CR28]\]. With the analysis of PMQR genes (*qnr* genes and *qepA* gene), the most frequent gene was *qnrB*, which was detected in (62.9%) of Q and FQs resistant isolates, and in (100%) of FQs resistant isolates while *qnrS* gene was detected in (46.9%) of Q and FQs resistant isolates and in (74.4%) of FQs resistant isolates. In other studies on Egyptian population, *qnrB* was the most prevalent *qnr* gene among *K. pneumoniae* isolates as denoted by El-Badawy et al., 2017 which agree with our results \[[@CR29]\], while others reported that *qnrS* was the most prevalent gene among gram negative bacilli isolated from different clinical settings \[[@CR10], [@CR11]\]. *QnrB* and *qnrS* genes detection rate in our study was higher than that reported in several previous studies \[[@CR27], [@CR30]\]. Neither *qnrA* nor *qnrC* were detected at all, but *qepA* gene was detected in (10%) of FQs resistant isolates. In the same context with us, several studies also could not detect *qnrA* gene among *Enterobacteriaceae* isolates \[[@CR27], [@CR30], [@CR31]\]. However, Szabó et al., 2018 could detect *qnrA* in their isolates but could not detect neither *qnrC* nor *qepA* genes \[[@CR32]\]. The difference between our results and others may be caused by geographical distribution of *qnr* genes, type of clinical isolates or the used methods of detection. With considering the analysis of the QRDRs of *gyrA* and *parC* genes, this study reported that the mutation at position 83 of *gyrA* was the most frequent in Q and FQs resistant strains. Three types of amino acid changes resulted from this mutation. Change from serine to leucine in *E. coli* strains which was also reported by many reports \[[@CR33], [@CR34]\] and change from serine to tyrosine which was detected in *K. pneumoniae* and *E. coli* and was also reported previously \[[@CR35]\]. The third change (from serine to isoleucine) was detected in *Citrobacter* strains and was reported in several studies \[[@CR36], [@CR37]\]. A double concomitant mutation in *gyrA* A (Lys154Arg and Ser171Ala) was observed in high FQs resistant C*itrobacter* spp. isolates with MIC of CIP ≥ 256 μg/mL and *E. coli* isolates with MIC of CIP ≥128 μg/mL. These mutations were reported previously in few studies \[[@CR35], [@CR38]\]. Asp-87 Asn mutation of *gyr*A gene was the least frequent mutation, where it was detected only in high resistant *E. coli* isolates with MIC ≥128 μg/mL. Therefor the mutation at position 87 of *gyrA* seemed to contribute to high resistance to FQs, while the mutation at position 83 could contribute to both Q and FQs resistance. This suggestion agrees with other results \[[@CR34], [@CR39]\]. Ser80Ile mutation of *parC* gene was frequent in both Q and FQs resistant strains that agrees with other studies \[[@CR40], [@CR41]\]. Single mutation in either gene occurred only in isolates with MIC of CIP ≤ 2 μg/mL, so the presence of double mutation in *gyrA* and *parC* genes seemed to be associated with high levels of resistance to FQs. These findings agree with other reports suggested that high levels of FQs resistance appeared to happen as a result of gradual accumulation of QRDR mutations \[[@CR38], [@CR42]\]. All isolates with high and intermediate resistance phenotypes harbored one or more PMQR gene, interestingly, isolates with FQs susceptible phenotype (resistant to NA only) harbored none of the tested PMQR genes. This agrees with Rodrı'guez-Martı'nez et al., 2016, who stated that resistance to NA only is not enough to suggest presence of PMQR genes \[[@CR43]\], while Szabó and his colleagues could found PMQR genes among susceptible or low-level resistance to ciprofloxacin with (MIC = 0.06--1 mg/L) isolates \[[@CR32]\]. Our study also agrees with Piekarska et al., 2015, who stated that combination of both PMQR genes and mutations in QRDRs of *gyrA* and *parC* contributes to high resistance to FQs \[[@CR9]\].

Conclusion {#Sec17}
==========

In the current study *Enterobactericeae* remain the most common cause of UTIs. The resistance rate of Q is (32.5%), while the resistance to Q and FQs is (20.5%) among *Enterobactericeae* isolates. At least one of PMQR gene was detected in FQs resistant isolates. The most frequent gene was *qnrB*, which was detected in (62.9%) of Q resistant isolates followed by *qnrS* gene which was detected with a percentage of (46.9%). The co-existence of 2 PMQR genes in the same isolate was observed in (46.9%) of resistant isolates, while co-existence of 3 PMQR genes was reported in (6.3%). The presence of at least two PMQR genes together with simultaneous QRDR mutations in each of *gyrA* and *parC* genes can describe the mechanism of resistance in high resistance phenotype (highly resistant to all tested Q and FQs), while presence of at least one PMQR gene together with one QRDR mutation at either genes could be the cause of resistance in isolates with intermediate resistance phenotype (intermediate resistance to all tested Q and FQs). Presence of mutation in only one QRDR regions of *gyrA* or *parC* genes could be the cause of resistance to NA only. To our knowledge, the current study is the largest study that reported molecular epidemiology of quinolones resistance in different *Enterobacteriaceae* species in the study area and could suggest a phenotypic algorithm to describe genetic mechanisms of quinolone resistance.
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 {#Sec18}

**Additional file 1: Figure S1.** Agarose gel electrophoresis (1%) for separation of multiplex PCR products; M is molecular size marker (100 bp ladder), lanes: 1, 2, 3 are positive for *qnrB* and *qnrS*, 4, 5 are positive for *qnrB*. The size of PCR products (in base pairs) is indicated on the right. **Additional file 2: Figure S2.** Agarose gel electrophoresis (1%) for separation of PCR products of *qepA*; M is molecular size marker (100 bp ladder), lanes: 1, 2, 3, 4, 5, 6, 9 are positive for *qepA,* 7, 8 are negative for *qepA* gene. The size of PCR product (in base pairs) is indicated on the right.
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:   Community-acquired urinary tract infection
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